Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.
The study, led by a team in The Research Institute at Nationwide Children’s Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allows cells to skip over missing parts of the gene and produce protein naturally.
“I’ve been doing this for more than 40 years and this is one of the most exciting developments we’ve seen,” says Jerry Mendell, MD, lead author of the study and director of the Center for Gene Therapy at Nationwide Children’s. “It offers great hope to patients with and their families.”
The research, which appears online Aug. 1 in the journal Annals of Neurology, is the first study from a double-blind controlled randomized trial of an exon-skipping agent to provide conclusive proof based on the standard six-minute walk test used to measure muscle function in patients with Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy in children.
About one in every 5,000 male births in the U.S. has the disorder, which usually leaves patients unable to walk on their own by age 12. Children with DMD have a mutation that cripples the body’s ability to produce a protein called dystrophin, which helps absorb the shock or energy that’s created when a muscle contracts. Without it, that released energy injures muscle fibers. Over time, the muscle degenerates, scar tissue builds up and fat slowly replaces the dead muscle.
The exact mutation varies from patient to patient but in 65 percent of cases, the dystrophin gene is missing large sections of DNA called exons, which carry the instructions for protein production. Accompanying this type of mutation is a spontaneously occurring reaction that enables muscle cells to skip over the deleted sections and produce smaller—but functional—versions of protein.
Eteplirsen, manufactured by Sarepta Therapeutics in Cambridge, Mass., mimics this naturally occurring phenomenon, allowing cells to skip over exon 51 in the dystrophin gene. About 13 percent of patients with the disorder have this mutation. Nationwide Children’s began the phase II trial of eteplirsen in August 2011, enrolling 12 boys age 7 to 12 years.
Participants received the drug via weekly IVs, with one group getting a 30 mg/kg dose and another group receiving 50 mg/kg. A control group received a placebo. Participants completed a six-minute walk test at the outset and again at weeks 12, 24 and 48. Muscle biopsies were also taken when the study began and again at those intervals to measure for dystrophin-positive muscle fibers.
Although there was no dystrophin production at 12 weeks, participants showed a 23 percent increase in dystrophin-positive muscle fibers by the 24-week mark. The striking improvement and lack of side effects prompted researchers to switch participants in the placebo group to the drug. By week 48, participants had a 52 percent increase in dystrophin-positive muscle fibers and were able to walk 67.3 meters farther than the placebo group on the six-minute walk test.
Although the results are promising, Dr. Mendell is quick to note that the small study leaves many questions unanswered.
The Latest on: Duchenne Muscular Dystrophy
- Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophyon December 2, 2019 at 8:31 am
Biomarkers for monitoring of disease progression and response to therapy are lacking for muscle diseases such as Duchenne muscular dystrophy. Noninvasive in vivo molecular imaging with multispectral ...
- Translational Study Demonstrates Value of MSOT Imaging for the Assessment of Disease Progression in Duchenne Muscular Dystrophyon December 2, 2019 at 7:00 am
MUNICH, Dec. 2, 2019 /PRNewswire-PRWeb/ -- DMD is the most common lethal inherited muscular disease occurring in about one of 5,000 male births. While affected boys can develop normally, at the age of ...
- UMass Medical School Works To Ease Challenge Of Duchenne Muscular Dystrophyon November 29, 2019 at 5:10 am
WORCESTER (CBS) — Caring for a child with Duchenne Muscular Dystrophy can be incredibly challenging, but thanks to a local family’s philanthropy and a local medical school’s commitment, treatment is ...
- Parent Project Muscular Dystrophy Launches New Duchenne Registry Appon November 22, 2019 at 1:59 pm
Leading Duchenne Organization Enhances 12-Year-Old Registry with New App, Empowering Families to Become Citizen Scientists by Contributing Data from the Palm of their Hand HACKENSACK, N.J., Nov. 12, ...
- Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 19, 2019 at 7:48 pm
Buyse, MD, PhD, Professor of Pediatrics and Child Neurology, University Hospitals Leuven (Leuven, Belgium). About Duchenne Muscular Dystrophy DMD is one of the most common and devastating types of ...
- Duchenne Muscular Dystrophy: Rep. Frey, Gov. Lamont raise awareness for rare diseaseon November 19, 2019 at 1:51 pm
In this season of thanks, Ridgefield residents Christopher and Jessica Curran expressed gratitude to both State Representative John Frey (R-111) and Governor Ned Lamont for working together in a ...
- JAR 914: Father Declares War on Duchenne Muscular Dystrophyon November 19, 2019 at 12:56 pm
Outline: New Jersey dad declares war on son's incurable disease - Duchenne Muscular Dystrophy. JAR of Hope nonprofit funds start of medical infusions to slow rare disease that effects 20,000 in U.S..
- Press Release: Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 10:03 pm
reduced from -5.9% 'Off-Idebenone' to -1.9% 'On-Idebenone'. -- The annual rate of decline in FVC%p and PEF%p remained stable year after year for the entire follow-up time of up to six years and was ...
- A distant dream for us with muscular dystrophyon November 18, 2019 at 5:26 am
Most common and severe form of muscular dystrophy is Duchenne Muscular Dystrophy (DMD) which typically affects young boys. Less severe is Becker Muscular Dystrophy (BMD) which is similar in symptoms ...
- Duchenne Muscular Dystrophy Therapeutics Market Strategic Assessment by Top Players | Sarepta Therapeutics, Inc, Santhera Pharmaceuticalson November 13, 2019 at 10:12 pm
Nov 14, 2019 (WiredRelease via COMTEX) -- Duchenne Muscular Dystrophy Therapeutics Market by Growth 2020 – Technological Strategies, Business Advancements and Top-Vendor Landscape 2029, anticipated to ...
via Google News and Bing News